Medicxi launch­es a di­a­betes up­start with $11M; Ar­row­head part­ners on hep B; Im­munother­a­py start­up gains $12.2M round

The Medicxi ven­ture group has com­mit­ted up to 10 mil­lion eu­ros to back a spin­out fo­cus­ing on di­a­betes and meta­bol­ics. The up­start Ky­mo Ther­a­peu­tics will pur­sue Metabrain Re­search’s work on kynure­nine me­tab­o­lism in­hibitors for im­mune in­flam­ma­to­ry dis­or­ders, in­clud­ing type 2 di­a­betes. Pro­vid­ing they can nail down proof of con­cept da­ta, the in­vestors plan to seek out part­ners to help fund fur­ther work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER